Literature DB >> 8552864

Prevalence of pneumonia due to Legionella pneumophila and Mycoplasma pneumoniae in a population admitted to a department of internal medicine.

M Bozzoni1, L Radice, A Frosi, S Vezzoli, A Cuboni, F Vezzoli.   

Abstract

We studied 177 patients with pneumonia admitted to an internal medicine department over a period of 3 years to determine the incidence of two emerging pathogens, Legionella pneumophila and Mycoplasma pneumoniae. Clinical, radiological and laboratory tests were performed and included blood cultures, serology, gram staining and sputum cultures. L. pneumophila was the agent involved in 9 patients (5.1%) and M. pneumoniae in 12 (6.8%). These prevalences were about in the middle of the range of previously published figures. Legionella pneumonia is a rare illness, which even in the absence of suggestive clinical signs must be considered because of its possibly serious course and to allow appropriate therapeutic decisions to be made.

Entities:  

Mesh:

Year:  1995        PMID: 8552864     DOI: 10.1159/000196475

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  4 in total

1.  Characterization of a macrophage-specific infectivity locus (milA) of Legionella pneumophila.

Authors:  O S Harb; Y Abu Kwaik
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

2.  Essential role for the Legionella pneumophila rep helicase homologue in intracellular infection of mammalian cells.

Authors:  O S Harb; Y Abu Kwaik
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Identification of the aspartate-beta-semialdehyde dehydrogenase gene of Legionella pneumophila and characterization of a null mutant.

Authors:  O S Harb; Y Abu Kwaik
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Polymerase chain reaction for detection of Legionellae DNA in urine samples from patients with community-acquired pneumonia.

Authors:  M Socan; D Kese; N Marinic-Fiser
Journal:  Folia Microbiol (Praha)       Date:  2000       Impact factor: 2.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.